PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
Summary
USPTO published patent application US20260091024A1 for substituted riluzole prodrug compositions useful for treating cancers including melanoma, breast cancer, brain cancer, and prostate cancer. The prodrugs are designed for oral administration with enhanced stability to hepatic metabolism, releasing riluzole in plasma via enzymatic or biophysical processes. Inventors include Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, and Haiyan Bian. Application No. 19064963 was filed February 27, 2025.
What changed
USPTO published patent application US20260091024A1 (A1) on April 2, 2026, covering pharmaceutical compositions of substituted riluzole prodrugs for cancer treatment. The invention addresses melanoma, breast cancer, brain cancer, and prostate cancer through prodrugs that release riluzole in systemic circulation following oral administration. The prodrugs demonstrate enhanced stability to hepatic metabolism and are cleaved to release the active compound via enzymatic or general biophysical release processes. CPC classifications span A61K therapeutic preparations and C07D heterocyclic compounds.
This publication is informational and does not impose compliance obligations. Pharmaceutical companies developing oncology therapeutics, generic riluzole formulations, or drug delivery systems may wish to review this application to assess potential freedom-to-operate considerations or competitive landscape implications. Patent prosecution timelines and potential claims should be monitored through USPTO databases.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
Application US20260091024A1 Kind: A1 Apr 02, 2026
Inventors
Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, Haiyan Bian
Abstract
Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
CPC Classifications
A61K 31/428 A61K 9/006 A61K 9/1617 A61K 9/2004 A61K 31/454 A61K 31/496 A61K 31/5377 A61K 38/05 A61K 38/06 A61K 45/06 A61P 25/00 A61P 25/28 C07D 277/82 C07D 417/12 C07K 5/06026 C07K 5/0806 C07K 5/0808 C07K 5/0812 A61K 9/0056 A61K 9/2018 A61K 9/2063 A61K 9/485 A61K 9/4858 A61K 9/4866 A61K 2300/00
Filing Date
2025-02-27
Application No.
19064963
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.